相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1
Burcak Ozes et al.
GENE THERAPY (2022)
Satisfaction with ankle foot orthoses in individuals withCharcot-Marie-Tooth disease
Riccardo Zuccarino et al.
MUSCLE & NERVE (2021)
Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms
Mariarita Laforgia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Dysregulation of myelin synthesis and actomyosin function underlies aberrant myelin in CMT4B1 neuropathy
Marta Guerrero-Valero et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A
Suzan Boutary et al.
COMMUNICATIONS BIOLOGY (2021)
Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases
Anthony Tucker-Bartley et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2021)
AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1A
Benoit Gautier et al.
NATURE COMMUNICATIONS (2021)
Advances in the treatment of neuropathic pain
Nadine Attal et al.
CURRENT OPINION IN NEUROLOGY (2021)
Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies
Chiara Pisciotta et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2021)
Treadmill training in patients affected by Charcot-Marie-Tooth neuropathy: results of a multicenter, prospective, randomized, single-blind, controlled study
L. Mori et al.
EUROPEAN JOURNAL OF NEUROLOGY (2020)
Neuropathic pain in patients with Charcot-Marie-Tooth type 1A
Bogdan Bjelica et al.
NEUROLOGICAL SCIENCES (2020)
Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice
Ji-Su Lee et al.
NUCLEIC ACIDS RESEARCH (2020)
Diabetic neuropathy: what does the future hold?
Brian C. Callaghan et al.
DIABETOLOGIA (2020)
HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice
Cristina Picci et al.
EXPERIMENTAL NEUROLOGY (2020)
Pregnancy outcome in Charcot-Marie-Tooth disease: results of the CMT-NET cohort study in Germany
S. Rudnik-Schoeneborn et al.
EUROPEAN JOURNAL OF NEUROLOGY (2020)
A Consensus Statement on the Surgical Treatment of Charcot-Marie-Tooth Disease
Glenn B. Pfeffer et al.
FOOT & ANKLE INTERNATIONAL (2020)
Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes
Andrea Cortese et al.
NATURE GENETICS (2020)
Myelin protein zero gene dose dependent axonal ion-channel dysfunction in a family with Charcot-Marie-Tooth disease
Mihai Moldovan et al.
CLINICAL NEUROPHYSIOLOGY (2020)
Pregnancy in Charcot-Marie-Tooth disease Data from the Italian CMT national registry
Chiara Pisciotta et al.
NEUROLOGY (2020)
Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy
Natasa Schiza et al.
BRAIN (2019)
Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity
Amanda Wallace et al.
NEUROLOGY (2019)
Enhanced axonal neuregulin-1 type-III signaling ameliorates neurophysiology and hypomyelination in a Charcot-Marie-Tooth type 1B mouse model
Cristina Scapin et al.
HUMAN MOLECULAR GENETICS (2019)
Gene therapy targeting SARM1 blocks pathological axon degeneration in mice
Stefanie Geisler et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1
Vera Fridman et al.
NEUROLOGY (2019)
PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models
Hien Tran Zhao et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
PREVALENCE AND ORTHOPEDIC MANAGEMENT OF FOOT AND ANKLE DEFORMITIES IN CHARCOT-MARIE-TOOTH DISEASE
Matilde Laura et al.
MUSCLE & NERVE (2018)
Elevated Peripheral Myelin Protein 22, Reduced Mitotic Potential, and Proteasome Impairment in Dermal Fibroblasts from Charcot-Marie-Tooth Disease Type 1A Patients
Sooyeon Lee et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
Pain in Charcot-Marie-Tooth disease: an update
Helen Azevedo et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2018)
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease
Veronick Benoy et al.
BRAIN (2018)
LOCALLY ACTING ACE-083 INCREASES MUSCLE VOLUME IN HEALTHY VOLUNTEERS
Chad E. Glasser et al.
MUSCLE & NERVE (2018)
Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B
Yunhong Bai et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy
R. Fledrich et al.
NATURE COMMUNICATIONS (2018)
Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability
M. J. Ibanez-Julia et al.
ACTA ONCOLOGICA (2018)
Pmp22 mutant allele-specific siRNA alleviates demyelinating neuropathic phenotype in vivo
Ji-Su Lee et al.
NEUROBIOLOGY OF DISEASE (2017)
221st ENMC International Workshop: Foot Surgery in Charcot-Marie-Tooth disease. 10-12 June 2016, Naarden, The Netherlands
Mary M. Reilly et al.
NEUROMUSCULAR DISORDERS (2017)
Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: a randomised, double-blind, sham-controlled trial
Joshua Burns et al.
LANCET CHILD & ADOLESCENT HEALTH (2017)
Niacin-mediated Tace activation ameliorates CMT neuropathies with focal hypermyelination
Alessandra Bolino et al.
EMBO MOLECULAR MEDICINE (2016)
Efficacy of focal mechanic vibration treatment on balance in Charcot-Marie-Tooth 1A disease: a pilot study
Costanza Pazzaglia et al.
JOURNAL OF NEUROLOGY (2016)
Rehabilitation Management of the Charcot-Marie-Tooth Syndrome A Systematic Review of the Literature
Bruno Corrado et al.
MEDICINE (2016)
Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy
Giovanna Sociali et al.
NEUROBIOLOGY OF DISEASE (2016)
Progression of motor axon dysfunction and ectopic Nav1.8 expression in a mouse model of Charcot-Marie-Tooth disease 1B
Mette R. Rosberg et al.
NEUROBIOLOGY OF DISEASE (2016)
An oral NaV1.8 blocker improves motor function in mice completely deficient of myelin protein P0
Mette R. Rosberg et al.
NEUROSCIENCE LETTERS (2016)
Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy
Alexia Kagiava et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Rehabilitation issues in Charcot-Marie-Tooth disease
Ozge Kenis-Coskun et al.
JOURNAL OF PEDIATRIC REHABILITATION MEDICINE (2016)
Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease
Irene Sargiannidou et al.
ANNALS OF NEUROLOGY (2015)
Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice
Dennis Klein et al.
BRAIN (2015)
Systematic review of exercise for Charcot-Marie-Tooth disease
Amy D. Sman et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2015)
Ascorbic acid for the treatment of Charcot-Marie-Tooth disease
Burkhard Gess et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
A pilot study of proximal strength training in Charcot-Marie-Tooth disease
Gita M. Ramdharry et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2014)
PAIN AND SMALL FIBER FUNCTION IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A
Matilde Laura et al.
MUSCLE & NERVE (2014)
Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A
Robert Fledrich et al.
NATURE MEDICINE (2014)
Effect of pain in pediatric inherited neuropathies
Sindhu Ramchandren et al.
NEUROLOGY (2014)
Quality-of-life in Charcot-Marie-Tooth disease: The patient's perspective
Nicholas E. Johnson et al.
NEUROMUSCULAR DISORDERS (2014)
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
Shahram Attarian et al.
ORPHANET JOURNAL OF RARE DISEASES (2014)
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy
Ilya Chumakov et al.
ORPHANET JOURNAL OF RARE DISEASES (2014)
Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine
Edward C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice
Agnes Patzko et al.
BRAIN (2012)
Exploring the experience of fatigue in people with Charcot-Marie-Tooth disease
Gita M. Ramdharry et al.
NEUROMUSCULAR DISORDERS (2012)
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
Davide Pareyson et al.
LANCET NEUROLOGY (2011)
HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease
Constantin d'Ydewalle et al.
NATURE MEDICINE (2011)
PRPS1 Mutations: Four Distinct Syndromes and Potential Treatment
Arjan P. M. de Brouwer et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2010)
Fatigue, reduced sleep quality and restless legs syndrome in Charcot-Marie-Tooth disease: a web-based survey
Matthias Boentert et al.
JOURNAL OF NEUROLOGY (2010)
Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: A laser-evoked potential study
Costanza Pazzaglia et al.
PAIN (2010)
P2X7-mediated Increased Intracellular Calcium Causes Functional Derangement in Schwann Cells from Rats with CMT1A Neuropathy
Lucilla Nobbio et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Benefits of interval-training on fatigue and functional capacities in Charcot-Marie-Tooth disease
Lhassan El Mhandi et al.
MUSCLE & NERVE (2008)
Spinal deformities in hereditary motor and sensory neuropathy - A retrospective qualitative, quantitative, genotypical, and familial analysis of 175 patients
Ondrej Horacek et al.
SPINE (2007)
Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy
Gerd Meyer zu Horste et al.
ANNALS OF NEUROLOGY (2007)
Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: A potential therapy for inherited neuropathy
Mehrdad Khajavi et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Effects of dynamic balance training during standing and stepping in patients with hereditary sensory motor neuropathy
Zlatko Matjacic et al.
DISABILITY AND REHABILITATION (2006)
Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression
J Fortun et al.
NEUROBIOLOGY OF DISEASE (2006)
NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients
Z Sahenk et al.
NEUROLOGY (2005)
Neuregulin-1 type III determines the ensheathment fate of axons
C Taveggia et al.
NEURON (2005)
Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease
E Passage et al.
NATURE MEDICINE (2004)
Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: Recommendations for exercise prescription
RD Chetlin et al.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2004)
Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease
RD Chetlin et al.
MUSCLE & NERVE (2004)
Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)
MW Sereda et al.
NATURE MEDICINE (2003)
分享论文
